begelomab
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02411084)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dipeptidyl peptidase IVINHIBITOR
DPP4 inhibitor
Inhibits the activation of T-cells reducing the immune response occurring during steroid resistant aGvHD.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3833357 ↗
Also known as
- begelomab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02411084 | Phase 3 | Feb 1, 2016 | Adienne SA |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adienne SA | For profit | 1 | 1 | 1 | 2016 |
1 organizations
Page 1 / 1